OROSOL : treatment for oral mucositis

Overview

OROSOL is a revolutionary product designed to provide relief and treatment for oral mucositis induced by radiotherapy or chemotherapy. This throat spray, presented in a 20ml bottle, targets pro-inflammatory proteins, contaminants, and impurities, offering a threefold action for optimal results.

Mode of action

Protective Barrier Effect:

MucositisOROSOL creates a protective barrier in the oral cavity, shielding the mucous membranes from further damage and allowing the healing process to begin.

Osmotic and Cleaning Effect:

The product works to cleanse the oral cavity, removing impurities and contaminants that can exacerbate inflammation and delay healing.

Cellular Repair and Growth Effect:

MucositisOROSOL promotes the repair and growth of cells in the oral cavity, accelerating the healing process and reducing the duration of symptoms.

Clinical Trial

Participants: The study included 69 patients with oral mucositis, with 48 in the OROSOL® group and 21 in the classical treatment (CT) group. Patients were between the ages of 7 and 91 years, with a mean age of 54.68 years.

Treatment: OROSOL®, an osmotically active hypertonic solution containing specific protease-inhibiting plant procyanidins, was sprayed over the oral mucosa 4-5 times per day for 28 days.

Mucositis Grade:

• The mean mucositis score reduced significantly in the OROSOL® group from 2.67 at the start to 0.83 on day 28, indicating nearly 70% reduction.
• In the CT group, the mean mucositis score reduced slightly from 2.33 to 2.10 on day 28, indicating a 10% reduction.

Pain Reduction:

• The mean pain intensity score in the OROSOL® group decreased from 7.19 at the start to 2.05 on day 28.
• In the CT group, the pain intensity reduced from 7.14 to 5.71.

Burning Sensation:

• The burning sensation score in the OROSOL® group reduced from 7.25 at the start to 1.92 on day 28.
• In the CT group, the burning sensation score reduced from 6.81 to 5.76.

Infection:

• The mean infection score in the OROSOL® group decreased from 2.10 at the start to 0.52 on day 28.
• In the CT group, the infection score decreased from 2.43 to 1.95.

New Ulcer Formation:

• In the OROSOL® group, new ulcer formation reduced slightly but significantly, while in the CT group, the number of ulcers remained nearly constant.

Eating Difficulty:

• The eating difficulty score in the OROSOL® group reduced from 2.81 at the start to 1.50 on day 28.
• In the CT group, the score decreased from 2.62 to 2.38.

Safety:

• OROSOL® was well-tolerated, with only slight initial burning sensation followed by salivation after application, which was temporary.

Conclusion: OROSOL® significantly reduces the severity of oral mucositis, pain, burning sensation, infection, and eating difficulty. It is a promising new therapeutic approach for treating oral mucositis of multiple origins

See full publication (PDF)